PFE - Structure Therapeutics: Yet Another Potential GLP-1 Entrant

2024-06-14 10:24:55 ET

Summary

• Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals.
• However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatment landscape.
• The company used the spike in the stock to raise additional capital this month.
• Can Structure compete against Eli Lilly, Novo Nordisk and a host of other potential entrants in an increasingly crowded GLP-1 space?
• We look at the GLP-1 competitive landscape as well as Structure's prospects in the paragraphs below.

Shares of GLP-1 concern Structure Therapeutics Inc. ( GPCR ) rallied over 50% after updated data suggests that its GSBR-1290 can compete with other oral GLP-1R clinical rivals. That said, its efficacy at week 12 is far below that demonstrated by Novo Nordisk’s ( NVO ) next-generation oral dual (GLP-1 and amylin) agonist amycretin. The secondary offering met by this rally merited a deeper dive into both Structure and the entire obesity treatment landscape. An analysis follows below....

For further details see: